Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 9/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16471295 | 0.77 | KMT2A (0.30) | KMT2A | |
| SCHEMBL16471341 | 0.77 | KMT2A (0.36) | KMT2A | |
| SCHEMBL16478056 | 0.77 | TRPV4 (0.52) | TRPV4IDO1ARCYP11B2SLC22A12 | |
| SCHEMBL12960442 | 0.76 | AR (0.45) | AR | |
| SCHEMBL16471349 | 0.76 | — | — | |
| SCHEMBL7831167 | 0.74 | TRPV4 (0.48) | TRPV4IDO1ARCYP11B2SLC22A12 | |
| SCHEMBL16471319 | 0.74 | KMT2A (0.41) | KMT2A | |
| SCHEMBL30872749 | 0.74 | TRPV4 (0.48) | TRPV4IDO1ARCYP11B2SLC22A12 | |
| SCHEMBL16471313 | 0.71 | EPAS1 (0.33) | SLC22A12 | |
| SCHEMBL9859393 | 0.70 | MAPK1 (0.63) | TRPV4IDO1ARCYP11B2SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TRPV4 4682/4885IDO1 571/4885KMT2A 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.